Analysts put BMS on takeover menu

Analysts are salivating over Bristol-Myers Squibb. Healthy earnings and sales growth, coupled with a stock price down by about a third since last July, makes the drugmaker "an attractive takeover candidate for a larger pharma," a Zacks Investment Research analyst wrote to investors, upgrading the stock to "buy" from "hold." A Standard & Poor's analyst concurs, saying BMS "could offer significant value in a merger with the right partner."

And just which Big Pharma might that partner be? Zacks mentioned Pfizer and Sanofi-Aventis, which have worked with Bristol on some products. Plavix, for instance, is a joint promo with Sanofi, and the anti-clotting drug is growing fast; plus, the med may also help cut risk of heart attack or stroke in atherosclerosis patients. But Plavix's patent expires in 2011--and that's where Pfizer speculation comes in. It's Bristol's development partner on Apixaban, another anti-clotting product.

- read the story in Business Week

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.